Home › NDC Lookup › RxCUI directory › RxCUI 1551782

Naloxegol 25 MG Oral Tablet — RxCUI 1551782

RxNorm drug concept · Semantic clinical drug
RxCUI 1551782 Semantic clinical drug · SCD ● Current RxNorm concept 3 FDA products 12 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1551782
Official nameNaloxegol 25 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asnaloxegol 25 MG (as naloxegol oxalate 28.5 MG) Oral Tablet
FDA products mapped3
Package NDCs mapped12
Reported Medicaid activity (SDUD)56,672 prescriptions · 49 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Naloxegol: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Opioid pain medications like oxycodone or hydrocodone attach to receptors throughout your body — including your gut — and slow down how quickly things move through your intestines....
  • Why am I constipated from my pain medication, and how does Movantik help?
  • Yes — you should stop regular laxatives before you begin Movantik. If after three days you still aren't getting enough relief, laxatives can be added back on an as-needed basis. Yo...
  • Do I need to stop my laxatives before starting Movantik?
📖 Read our full Naloxegol guide →

🕸️ Concept Web — How Naloxegol 25 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Naloxegol 25 MG Oral Tablet RxCUI 1551782

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Naloxegol 1551777
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Movantik 1551918
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Naloxegol Oral Tablet 1551781
    • Naloxegol Oral Product 1551779
    • Naloxegol Pill 1551780
    • Naloxegol Oral Tablet [Movantik] 1551920
    • Movantik Oral Product 1551921
    • Movantik Pill 1551922
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Naloxegol 25 MG SCDC · 1551778
  • Naloxegol Oral Tablet SCDF · 1551781
  • Naloxegol Oral Product SCDG · 1551779
  • Naloxegol Pill SCDG · 1551780

Brand-Name Concepts

  • Naloxegol 25 MG Oral Tablet [Movantik] SBD · 1601373
  • Naloxegol 25 MG [Movantik] SBDC · 1601372
  • Naloxegol Oral Tablet [Movantik] SBDF · 1551920
  • Movantik Oral Product SBDG · 1551921
  • Movantik Pill SBDG · 1551922
  • Movantik BN · 1551918

📦 FDA Products & Package NDCs

3 products · 12 package NDCs
12 package NDCs map to RxCUI 1551782 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
57841-1301-01 30 TABLET, FILM COATED in 1 BOTTLE (57841-1301-1) MOVANTIK RedHill Biopharma Ltd 2020-10-01
57841-1301-02 90 TABLET, FILM COATED in 1 BOTTLE (57841-1301-2) MOVANTIK RedHill Biopharma Ltd 2020-10-01
57841-1301-03 10 BLISTER PACK in 1 CARTON (57841-1301-3) / 10 TABLET, FIL... MOVANTIK RedHill Biopharma Ltd 2020-10-01
57841-1301-04 1 BLISTER PACK in 1 CARTON (57841-1301-4) / 3 TABLET, FILM... MOVANTIK RedHill Biopharma Ltd 2020-10-01
82625-8801-01 30 TABLET, FILM COATED in 1 BOTTLE (82625-8801-1) MOVANTIK Valinor Pharma, LLC 2023-03-28
82625-8801-02 90 TABLET, FILM COATED in 1 BOTTLE (82625-8801-2) MOVANTIK Valinor Pharma, LLC 2023-03-28
82625-8801-03 10 BLISTER PACK in 1 CARTON (82625-8801-3) / 10 TABLET, FIL... MOVANTIK Valinor Pharma, LLC 2023-03-28
82625-8801-04 1 BLISTER PACK in 1 CARTON (82625-8801-4) / 3 TABLET, FILM... MOVANTIK Valinor Pharma, LLC 2023-03-28
82625-8802-01 30 TABLET, FILM COATED in 1 BOTTLE (82625-8802-1) MOVANTIK Valinor Pharma, LLC 2023-03-28
82625-8802-02 90 TABLET, FILM COATED in 1 BOTTLE (82625-8802-2) MOVANTIK Valinor Pharma, LLC 2023-03-28
82625-8802-03 10 BLISTER PACK in 1 CARTON (82625-8802-3) / 10 TABLET, FIL... MOVANTIK Valinor Pharma, LLC 2023-03-28
82625-8802-04 1 BLISTER PACK in 1 CARTON (82625-8802-4) / 3 TABLET, FILM... MOVANTIK Valinor Pharma, LLC 2023-03-28
Observed labelers: Valinor Pharma, LLC (8) · RedHill Biopharma Ltd (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.